At Curigin, we are developing innovative therapies using our novel bi-specific shRNA technology to simultaneously knockdown two different disease causing pathways. Our lead pipelines target cancer pathways such as mTOR and STAT3 and deliver our bi-specific shRNA through an oncolytic virus genetically engineered to exclusively target and replicate in cancer cells.